GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » Price-to-Free-Cash-Flow

ABBV (AbbVie) Price-to-Free-Cash-Flow : 19.79 (As of Dec. 11, 2024)


View and export this data going back to 2012. Start your Free Trial

What is AbbVie Price-to-Free-Cash-Flow?

As of today (2024-12-11), AbbVie's share price is $174.37. AbbVie's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $8.81. Hence, AbbVie's Price-to-Free-Cash-Flow Ratio for today is 19.79.

The historical rank and industry rank for AbbVie's Price-to-Free-Cash-Flow or its related term are showing as below:

ABBV' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.56   Med: 12.38   Max: 36.06
Current: 19.97

During the past 13 years, AbbVie's highest Price-to-Free-Cash-Flow Ratio was 36.06. The lowest was 7.56. And the median was 12.38.

ABBV's Price-to-Free-Cash-Flow is ranked better than
59.02% of 532 companies
in the Drug Manufacturers industry
Industry Median: 26.44 vs ABBV: 19.97

AbbVie's Free Cash Flow per Share for the three months ended in Sep. 2024 was $2.93. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $8.81.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of AbbVie was -36.80% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 7.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 10.90% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 19.60% per year.

During the past 13 years, AbbVie's highest 3-Year average Free Cash Flow per Share Growth Rate was 47.70% per year. The lowest was -20.50% per year. And the median was 11.65% per year.


AbbVie Price-to-Free-Cash-Flow Historical Data

The historical data trend for AbbVie's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Price-to-Free-Cash-Flow Chart

AbbVie Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.29 10.68 10.94 11.85 12.45

AbbVie Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.70 12.45 14.74 17.10 22.42

Competitive Comparison of AbbVie's Price-to-Free-Cash-Flow

For the Drug Manufacturers - General subindustry, AbbVie's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where AbbVie's Price-to-Free-Cash-Flow falls into.



AbbVie Price-to-Free-Cash-Flow Calculation

AbbVie's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=174.37/8.81
=19.79

AbbVie's Share Price of today is $174.37.
AbbVie's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.81.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

AbbVie  (NYSE:ABBV) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


AbbVie Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of AbbVie's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


AbbVie Business Description

Address
1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Executives
Richard A Gonzalez officer: Chairman of the Board and CEO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Nicholas Donoghoe officer: SVP, Enterprise Innovation 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jeffrey Ryan Stewart officer: SVP, US Commercial Operations 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Timothy J. Richmond officer: EVP, Chief HR Officer 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Kevin K Buckbee officer: SVP, Controller 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Perry C Siatis officer: EVP, GC and Secretary 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Robert A. Michael officer: VP, Controller 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Scott T Reents officer: SVP, Chief Financial Officer 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Azita Saleki-gerhardt officer: SVP, Operations 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Susan E Quaggin director 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jennifer L. Davis director 1 PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Elaine K. Sorg officer: Sr. V.P., U.S. Commercial Ops. 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Carrie C Strom officer: SVP & Pres Global Allerg Aesth 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Roxanne S Austin director 200 N SEPULVEDA BLVD, PO BOX 956 MS ES/001/A102, EL SEGUNDO CA 90245
Michael Severino officer: EVP, R&D and CSO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064